Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Ca3140119a1 chemical process asciminib patent?Asciminib synthesis patent novartis?Cn114369085a asciminib hydrochloride google patents?Novartis asciminib manufacturing process patent intermediate?Us8829195b2 asciminib patent google patents?
See the DrugPatentWatch profile for Jadenu
What is Jadenu and what is it used for? Jadenu is a medication developed by Novartis, specifically for the treatment of elevated serum transferrin saturation (TSAT) and elevated liver iron concentration (LIC) in patients with transfusional hemosiderosis due to sickle cell disease or other anemias. How long has Jadenu been available, and what are its origins? Jadenu is the brand name for deferiprone, an oral iron-chelating agent that has been in use since the late 1990s. It was first approved in 2005 for the treatment of iron overload in patients with beta-thalassemia major. Source 1: [1] DrugPatentWatch.com What are the benefits of Jadenu over other treatments for iron overload? Jadenu has been shown to effectively reduce serum iron levels and iron stored in the liver, while also minimizing the need for phlebotomy, a common treatment for iron overload. It is administered orally, which may be more convenient for patients compared to intravenous iron-chelating agents. Are there any potential side effects or warnings associated with Jadenu? Jadenu may cause gastrointestinal side effects such as nausea, vomiting, and diarrhea, as well as neutropenia, a low white blood cell count. Patients with a history of agranulocytosis or severe neutropenia may be at increased risk. Source 2: [2] Novartis Pharmaceuticals Corporation When does the patent for Jadenu expire? The Jadenu patent is set to expire in 2029, allowing for the potential entry of generic deferiprone into the market. Source 3: [3] DrugPatentWatch.com What is the typical dosage and administration of Jadenu? Jadenu is available in 125mg and 250mg tablets, which are administered orally three times a day. The dose may need to be adjusted based on serum iron levels and liver iron concentration. Sources: [1] DrugPatentWatch.com https://www.drugpatentwatch.com [2] Novartis Pharmaceuticals Corporation https://www.novartis.com [3] DrugPatentWatch.com https://www.drugpatentwatch.com Note: The information provided is accurate as of the available sources, but the expiration date for Jadenu's patent may be subject to change.
Other Questions About Jadenu :